Search results
Results from the WOW.Com Content Network
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right ...
A Reuters poll of analysts in August found the average forecast price for a deal was $77.90 a share. Genzyme's stock had dropped as much as 43% from a 2008 high of $83.25 after sales and profit ...
Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.
For premium support please call: 800-290-4726 more ways to reach us
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. [1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
Genzyme was fined $175 million by the FDA for manufacturing deficiencies. [39] Genzymes's competitors benefited [39] and Genzyme stocks fell. As a result, 2011 Genzyme was acquired by Sanofi in an hostile takeover in October 2011—engineered in part by then-CEO of Sanofi, Christopher Viehbacher— [40]: 219 for more than $20 billion. Termeer ...
French pharmaceutical giant Sanofi-Aventis (SNY) sent a letter to major U.S. biotech firm Genzyme (GENZ) proposing a friendly takeover valued at $69 a share, or $18.4 billion, several media ...
With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). 26 2006 Johnson & Johnson: Guidant: 24.2 37